Page 11 - Epic Sciences News Today

/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japans Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX...

MarketsandResearch.biz has presented updated research on Global Lung Cancer Liquid Biops Market 2021 by Company, Regions, Type and Application, Forecast to 2026 that offers fine intelligence that prepares market players to compete well against their toughest competitors on the basis of growth, sales, and other vital...

7 Molecular Diagnostics Recent Developments 7.1 Recent Developments - Importance and How to Use This Section 7.1.1 Importance of These Developments 7.1.2 How to Use This Section 7.2 Nucleix to Invest in Early-Stage Lung Cancer Dx 7.3 Invitae to Acquire Genosity for $200M 7.4 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test 7.5 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience 7.6 Natera Revenues Grow 35 Percent 7.7 AnchorDx Closes $40M Financing Round 7...

  Additionally, it provides a futuristic perspective on various factors that are likely to boost the Global Molecular Biomarkers for Cancer Detection and Management Market growth in the years to come. Besides, authors of the report have shed light on the factors that may hamper the growth of the Global Molecular Biomarkers for Cancer Detection and Management Market. The report also helps in understanding the Global Molecular Biomarkers for Cancer Detection and Management Market through key seg...

3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development 3.4.2 Single Cell Genomics Changes the Picture 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magnetoresistance based assay 4. Cancer Panels & Profiles Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section Biocartis Collaborating With GeneproDx, Endpoint H...

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic tr...

Truvian raises $105M, plans to submit benchtop blood-testing tech to FDA Benchtop blood testing startup Truvian raised $105 million in series C funding, which it plans to use to pave the way to submit its device for FDA clearance. Shares0 Truvian Sciences plans to seek FDA clearance and CLIA certification for its benchtop blood testing device. Photo credit: Truvian Sciences Truvian Sciences, a startup building a benchtop blood analyzer, raised $105 million in funding. The San Diego-based compa...

Exact Sciences Announces Fourth Quarter 2020 Results News provided by Share this article Share this article MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020. "Exact Sciences finished another transformative year by delivering strong fourth quarter results against a challenging backdrop because...

Global Proteomics Partnering Terms and Agreements Analysis Report 2020 News provided by Share this article Share this article ResearchAndMarkets.coms offering. The Global Proteomics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The...

Will Personalized Companion Diagnostics become the norm for diagnostics? Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for thi...